Kura Oncology CEO Troy Wilson buys $1.24 million Kura shares
At a glance
- $KURA today+4.37%last $7.40
- Vs industry peers+4.47 pts6-peer median −0.10% · far ahead
- Since Aug 25−45.5%from the first trade after the story
- 52-week range9.6% above low$6.75 – $13.90
- Cash runway~3 mo$57.9M cash ÷ $22.6M/mo burn · 10-Q
- In the headline$1.24 millionAmount
Nothing reported about kura oncology across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: There is a hard number in this story ($1.24 million) — the interesting part is how it compares with the last few like it.
- How the stock is trading: $KURA +4.37% in the latest session.
- Timing: It was published before the opening bell, so the next session was the first chance to trade on it.
Where the stock stands
Kura Oncology ($KURA) climbed 4.37% to $7.40 in the latest session. Over the past month it is down 24.3%. That leaves it 47% below its 52-week high of $13.90 and 9.6% above its low of $6.75, close to the bottom of its range. It has been a volatile year: the high was 2.1 times the low, so moves this size are not unusual for it.
What the filings say
In its latest report (10-Q, filed Nov 10, 2026), $KURA lost $70.2M over the quarter to Sep 30, 2026 on revenue of $22.8M (+9.4% QoQ). Operations used $202.8M of cash over the nine months to Sep 30, 2026 — about $22.6M a month — against $57.9M in cash on Sep 30, 2026. At that pace the cash covers about 3 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. It carried $9.8M of debt against $57.9M of cash on Sep 30, 2026 — net cash of $48.1M. Its most recent filings before this story: 10-Q on Aug 12, 2026, 8-K on Aug 12, 2026. Figures are as filed with the SEC; the $KURA page has the full statements.
How much coverage it is getting
Nothing new on Kura Oncology has come through Wook's feeds in the last 30 days, so this is still the most recent story on it.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Wook's supply-chain scanner shows no unusual stress in Health Care today.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $KURA page, and they say what management has disclosed without a reporter in between. Where several outlets agree is usually the news; where they differ is the angle. Wook AI, at the top of the page, can work out how far $KURA is from its high or compare this week's coverage with earlier weeks.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on August 25, 2026. $KURA has moved -45.55% ($13.59 to $7.40). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
